BiotechTube
AFT Pharmaceuticals

AFT Pharmaceuticals

AFT.NZPhase 3
Auckland, New ZealandFounded 1997100-250 employeesaftpharm.com

AFT Pharmaceuticals is a commercial-stage specialty pharma company with a significant presence in Australasia and growing operations in Asia. Its core business model involves licensing and marketing a wide range of pharmaceutical products, while its key growth driver is the global development and commercialization of its patented intravenous and oral analgesic, Maxigesic® (a fixed-dose combination of paracetamol/acetaminophen and ibuprofen). The company has successfully transitioned from a distributor to an innovator, with Maxigesic IV approved and launched in multiple countries and an extensive pipeline of line extensions.

Market Cap
$210.1M
+29.4% period
Pipeline
8
6 in Phase 3
Patents
10
granted
Publications
13
indexed

AFT.NZ · Stock Price

USD 3.43+0.78 (+29.43%)

Historical price data

AI Company Overview

AFT Pharmaceuticals is a commercial-stage specialty pharma company with a significant presence in Australasia and growing operations in Asia. Its core business model involves licensing and marketing a wide range of pharmaceutical products, while its key growth driver is the global development and commercialization of its patented intravenous and oral analgesic, Maxigesic® (a fixed-dose combination of paracetamol/acetaminophen and ibuprofen). The company has successfully transitioned from a distributor to an innovator, with Maxigesic IV approved and launched in multiple countries and an extensive pipeline of line extensions.

Analgesia / Pain ManagementConsumer HealthcareVarious (Portfolio)

Technology Platform

Patented platform based on the fixed-dose synergistic combination of paracetamol (acetaminophen) and ibuprofen for pain management, with formulations including intravenous, oral tablets, and oral suspension.

Pipeline

8
8 drugs in pipeline6 in Phase 3
DrugIndicationStageWatch
Combogesic® IV (fixed-dose combination containing acetaminop...Acute PainPhase 3
Maxigesic IV + IV Acetaminophen + IV Ibuprofen + Placebo IVPost Operative PainPhase 3
Maxigesic 325 + Acetaminophen + Ibuprofen + PlaceboDental PainPhase 3
Maxigesic® IVPostoperative PainPhase 3
Acetaminophen + Maxigesic 325 + Ibuprofen + PlaceboOsteoarthritisPhase 3

Funding History

2
Total raised:$25M
IPO$25MDec 11, 2015
SeedUndisclosedJun 15, 1997

Opportunities

Significant growth opportunity lies in securing a development and commercialization partner for Maxigesic IV in the United States, the world's largest pharmaceutical market.
Further geographic expansion in Asia and Europe through existing partners also presents substantial upside.
Line extensions of the Maxigesic platform (e.g., intranasal) could address new market segments.

Risk Factors

Key risks include failure to secure a U.S.
partner for Maxigesic IV, regulatory setbacks in target markets, patent challenges, and underperformance by international licensing partners.
The company also faces concentration risk in Australasia and competitive pressures on its portfolio business.

Competitive Landscape

Competes with generic analgesics, other non-opioid combinations, and opioids in the pain market. For its distribution business, faces competition from local pharma companies and large multinationals. Differentiation is driven by the patented Maxigesic formulation and deep regional expertise in Australasia.